Bioservo Q2’22: Inflection point delayed - Redeye

Redeye reduces our short-to mid-term estimates due to a lower estimated number of systems to be sold during 2023E and, to an extent, into 2024E. The estimate changes and new issues alter our Base Case to SEK 8 per share. We still see a compelling long-term case; however, the commercialization of Ironhand has taken longer than we expected.

Länk till analysen i sin helhet: https://www.redeye.se/research/854318/bioservo-q222-inflection-point-delayed?utm_source=finwire&utm_medium=RSS